Cargando…

Counting drugs to understand the disease: The case of measuring the diabetes epidemic

BACKGROUND: Diabetes prevalence increases globally with severe consequences for afflicted individuals and societies. Data on diabetes incidence and diabetes related mortality on a population level are, however, scarce. As an alternative to dedicated studies it has been suggested to use pharmacoepide...

Descripción completa

Detalles Bibliográficos
Autores principales: Støvring, Henrik, Andersen, Morten, Beck-Nielsen, Henning, Green, Anders, Vach, Werner
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1805738/
https://www.ncbi.nlm.nih.gov/pubmed/17313683
http://dx.doi.org/10.1186/1478-7954-5-2
_version_ 1782132487853441024
author Støvring, Henrik
Andersen, Morten
Beck-Nielsen, Henning
Green, Anders
Vach, Werner
author_facet Støvring, Henrik
Andersen, Morten
Beck-Nielsen, Henning
Green, Anders
Vach, Werner
author_sort Støvring, Henrik
collection PubMed
description BACKGROUND: Diabetes prevalence increases globally with severe consequences for afflicted individuals and societies. Data on diabetes incidence and diabetes related mortality on a population level are, however, scarce. As an alternative to dedicated studies it has been suggested to use pharmacoepidemiological databases that are readily available, at least in the Nordic countries. METHODS: For all 470,000 inhabitants in Funen County, Denmark, in the period 1992–2003, data on gender, date of birth, death and migration to and from the county, and any filled prescriptions of an anti-diabetic medication was obtained from the Odense Pharmaco-Epidemiological Database. RESULTS: Prevalence odds for use of an anti-diabetic medication rose annually 3.5% (95% confidence interval: 3.1%, 3.9%) for females, 4.5% (4.0%, 4.9%) for males. Corresponding incidence rates annually rose 4.8% (3.8%, 5.8%) for females, 4.5% (3.5%, 5.4%) for males. Mortality rates among treated annually declined 2.8% (1.4%, 4.1%) among females, 2.2% (0.9%, 3.5%) among males. The disequilibrium in absolute numbers between incidence and mortality among treated was the main driver for the increasing prevalence, while concurrent trends in incidence and diabetes related mortality only marginally affected prevalence trends. Trend estimates were insensitive to varying the length of the run-in period used for determining treatment status, except when using the naive and methodologically flawed run-in period of variable length. CONCLUSION: While pharmacoepidemiological databases provide a useful tool for monitoring pharmacologically treated diabetes, a dedicated diabetes database covering all prevalents and incidents is needed for a more detailed analysis of underlying causes and trends.
format Text
id pubmed-1805738
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-18057382007-03-14 Counting drugs to understand the disease: The case of measuring the diabetes epidemic Støvring, Henrik Andersen, Morten Beck-Nielsen, Henning Green, Anders Vach, Werner Popul Health Metr Research BACKGROUND: Diabetes prevalence increases globally with severe consequences for afflicted individuals and societies. Data on diabetes incidence and diabetes related mortality on a population level are, however, scarce. As an alternative to dedicated studies it has been suggested to use pharmacoepidemiological databases that are readily available, at least in the Nordic countries. METHODS: For all 470,000 inhabitants in Funen County, Denmark, in the period 1992–2003, data on gender, date of birth, death and migration to and from the county, and any filled prescriptions of an anti-diabetic medication was obtained from the Odense Pharmaco-Epidemiological Database. RESULTS: Prevalence odds for use of an anti-diabetic medication rose annually 3.5% (95% confidence interval: 3.1%, 3.9%) for females, 4.5% (4.0%, 4.9%) for males. Corresponding incidence rates annually rose 4.8% (3.8%, 5.8%) for females, 4.5% (3.5%, 5.4%) for males. Mortality rates among treated annually declined 2.8% (1.4%, 4.1%) among females, 2.2% (0.9%, 3.5%) among males. The disequilibrium in absolute numbers between incidence and mortality among treated was the main driver for the increasing prevalence, while concurrent trends in incidence and diabetes related mortality only marginally affected prevalence trends. Trend estimates were insensitive to varying the length of the run-in period used for determining treatment status, except when using the naive and methodologically flawed run-in period of variable length. CONCLUSION: While pharmacoepidemiological databases provide a useful tool for monitoring pharmacologically treated diabetes, a dedicated diabetes database covering all prevalents and incidents is needed for a more detailed analysis of underlying causes and trends. BioMed Central 2007-02-21 /pmc/articles/PMC1805738/ /pubmed/17313683 http://dx.doi.org/10.1186/1478-7954-5-2 Text en Copyright © 2007 Støvring et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Støvring, Henrik
Andersen, Morten
Beck-Nielsen, Henning
Green, Anders
Vach, Werner
Counting drugs to understand the disease: The case of measuring the diabetes epidemic
title Counting drugs to understand the disease: The case of measuring the diabetes epidemic
title_full Counting drugs to understand the disease: The case of measuring the diabetes epidemic
title_fullStr Counting drugs to understand the disease: The case of measuring the diabetes epidemic
title_full_unstemmed Counting drugs to understand the disease: The case of measuring the diabetes epidemic
title_short Counting drugs to understand the disease: The case of measuring the diabetes epidemic
title_sort counting drugs to understand the disease: the case of measuring the diabetes epidemic
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1805738/
https://www.ncbi.nlm.nih.gov/pubmed/17313683
http://dx.doi.org/10.1186/1478-7954-5-2
work_keys_str_mv AT støvringhenrik countingdrugstounderstandthediseasethecaseofmeasuringthediabetesepidemic
AT andersenmorten countingdrugstounderstandthediseasethecaseofmeasuringthediabetesepidemic
AT becknielsenhenning countingdrugstounderstandthediseasethecaseofmeasuringthediabetesepidemic
AT greenanders countingdrugstounderstandthediseasethecaseofmeasuringthediabetesepidemic
AT vachwerner countingdrugstounderstandthediseasethecaseofmeasuringthediabetesepidemic